FrancophonIA/ELRC3.0 huggingface dataset:
English: In a phase I study, neutrophil and platelet count nadirs occurred at 2 to 3 weeks after intravenous administration of a single dose of Xofigo.
Croatian: U ispitivanju faze I, vrijednosti broja neutrofila i trombocita bile su najniže 2 do 3 tjedna nakon intravenske primjene jedne doze lijeka Xofigo.
English: Whole body
Croatian: Maternica Cijelo tijelo
English: You might be at a higher risk of bone fractures.
Croatian: Možete imati veći rizik prijeloma kostiju.
English: Before subsequent administrations, the ANC should be ≥ 1.0 x 109/l and the platelet count ≥ 50 x 109/l.
Croatian: Prije sljedećih primjena, ABN treba biti ≥ 1,0 x 109/l i broj trombocita ≥ 50 x 109/l.
English: 3ULI: upper large intestine
Croatian: 3 GDC: gornji dio debelog crijeva
English: Subgroup survival analysis showed a consistent survival benefit for treatment with Xofigo, independent of use of bisphosphonates at baseline and prior use of docetaxel.
Croatian: Analiza preživljenja po podskupinama pokazala je dosljednu korist liječenja lijekom Xofigo za preživljenje, neovisno o primjeni bisfosfonata na početku liječenja i prethodnoj primjeni docetaksela.
English: Uncommon (may affect up to 1 in 100 people) - decrease in the number of lymphocytes, a type of white blood cells (lymphopenia) - weakened bones (osteoporosis)
Croatian: Manje često (mogu se javiti u do 1 na 100 osoba) - smanjenje broja limfocita, vrste bijelih krvnih stanica (limfopenija) - oslabljene kosti (osteoporoza)
English: An interim analysis from a clinical trial in chemotherapy-naïve patients with asymptomatic or mildly symptomatic castration resistant prostate cancer and progressive disease with bone metastases showed an increased risk of fractures and a trend for increased mortality among patients receiving Xofigo in combination with abiraterone acetate and prednisone/prednisolone compared to patients receiving placebo in combination with abiraterone acetate and prednisone/prednisolone (see section 5.1).
Croatian: Interim analiza iz kliničkog ispitivanja u bolesnika s asimptomatskim ili blago simptomatskim rakom prostate rezistentnim na kastraciju i s progresivnom bolešću s metastazama na kostima, koji prethodno nisu bili liječeni kemoterapijom, pokazala je povećan rizik prijeloma i trend porasta smrtnosti kod bolesnika koji su primali Xofigo u kombinaciji s abirateronacetatom i prednizonom/prednizolonom u odnosu na bolesnike koji su primali placebo u kombinaciji s abirateronacetatom i prednizonom/prednizolonom (vidjeti dio 5.1).
English: No data are available for patients with severe (CLCR < 30 mL/min) renal impairment or end-stage renal disease.
Croatian: Nema dostupnih podataka za bolesnike s teškim (CLCR < 30 ml/min) oštećenjem funkcije bubrega ili u završnom stadiju bolesti bubrega.
English: Grade 1 and 2 injection site reactions, such as erythema, pain and swelling, were reported in 1.2% of patients treated with Xofigo and in 0% of patients receiving placebo.
Croatian: Reakcije na mjestu injekcije stupnja 1 i 2, kao što su eritem, bol i otok, bile su zabilježene u 1,2% bolesnika liječenih lijekom Xofigo i u 0% bolesnika koji su primali placebo.
English: Storage of radiopharmaceuticals will be in accordance with national regulations on radioactive materials.
Croatian: Čuvanje radiofarmaceutika bit će u skladu s nacionalnim propisima o radioaktivnim materijalima.
English: Total dose (Gy/MBq)
Croatian: Ukupna doza (Gy/MBq)
English: Colourless Type I glass vial closed with a grey bromobutyl rubber stopper either with or without foil-clad made of Ethylene tetrafluoroethylene (ETFE), both capped with aluminium seal, containing 6 mL of solution for injection.
Croatian: Bočica od bezbojnog stakla tipa I, zatvorena sivim čepom od bromobutilne gume, sa zaštitnom folijom od etilen-tetra-fluoro-etilena (ETFA) ili bez zaštitne folije, u oba slučaja s aluminijskim prstenom, koja sadrži 6 ml otopine za injekciju.
English: Demographic and baseline disease characteristics (interim analysis population) were similar between the Xofigo and placebo groups and are shown below for Xofigo:
Croatian: Skupina koja je primala Xofigo i skupina koja je primala placebo bile su slične po demografskim i značajkama osnovne bolesti (populacija iz privremene analize) koje su niže prikazane za Xofigo:
English: Although radium-223 is predominantly an alpha emitter, gamma and beta radiation is associated with the decay of radium-223 and its radioactive daughter isotopes.
Croatian: Iako je radij-223 pretežno alfa-emiter, s raspadom izotopa radija-223 i njegovih radioaktivnih kćeri povezano je i gama i beta zračenje.
English: Safety and efficacy beyond 6 injections with Xofigo have not been studied.
Croatian: Sigurnost i djelotvornost više od 6 injekcija lijeka Xofigo nisu ispitane.
English: Xofigo contains sodium
Croatian: Xofigo sadrži natrij
English: Treatment benefit of Xofigo in adults with castration-resistant prostate cancer and only asymptomatic bone metastases is not established.
Croatian: Korist od liječenja lijekom Xofigo u odraslih s rakom prostate rezistentnim na kastraciju i samo asimptomatskim koštanim metastazama nije ustanovljena.
English: If you have been given more Xofigo than you should An overdose is unlikely.
Croatian: Ako primite više lijeka Xofigo nego što ste trebali
English: It is stored in a lead pot.
Croatian: Čuva se u olovnoj posudi.
English: Oral intake and fluid status of patients should be carefully monitored.
Croatian: Potrebno je pažljivo nadzirati peroralni unos tekućine i stanje hidracije bolesnika.
English: The results of the interim analysis and the updated analysis also showed a significant improvement in all main secondary endpoints in the Xofigo arm compared to the placebo arm (see Table 3).
Croatian: Rezultati privremene i ažurirane analize pokazali su također značajno poboljšanje i u svim glavnim sekundarnim ishodima u skupini liječenoj lijekom Xofigo u usporedbi sa skupinom koja je primala placebo (vidjeti Tablicu 3).
English: If you take or have taken bisphosphonates or other medicines to protect your bone health or steroids (e.g. prednisone/prednisolone) prior to treatment with Xofigo, please tell your doctor.
Croatian: Ako uzimate ili ste uzimali bisfosfonate ili druge lijekove za zaštitu zdravlja kostiju ili steroide (npr. prednizon/prednizolon) prije liječenja lijekom Xofigo, recite svom liječniku.
English: In EOD4 (“superscan”) patients, thrombocytopenia (all grades) was reported in 19.6% of patients treated with Xofigo and in 6.7% of patients receiving placebo.
Croatian: U EOD4 („superscan“) bolesnika, prijavljena je trombocitopenija (svi stupnjevi) u 19,6% bolesnika liječenih lijekom Xofigo i u 6,7% bolesnika koji su primali placebo.
English: Data on a safe period after which Xofigo can be administered following treatment with abiraterone acetate in combination with prednisone/prednisolone and vice versa is limited.
Croatian: Ograničeni su podaci o sigurnosnom razdoblju nakon kojeg se Xofigo može primijeniti poslije liječenja abirateronacetatom u kombinaciji s prednizonom/prednizolonom, i obrnuto.
English: Xofigo must not be used if discolouration, the occurrence of particulate matter or a defective container is noticed.
Croatian: Xofigo se ne smije upotrijebiti ako primijetite promjenu boje, prisutnost čestica ili oštećenje spremnika.
English: The MAH shall conduct and submit the results of a non-interventional post-authorisation safety study (PASS) based on the data from the Prostate Cancer Data Base Sweden (PCBaSe) and other relevant Scandinavian cancer registers or other suitable data sources, in order to further characterise the safety of radium-223 in the authorized indication.
Croatian: Prostate Cancer Data Base Sweden, PCBaSe) i drugih relevantnih skandinavskih registara za rak ili drugih odgovarajućih izvora podataka kako bi se bolje opisala sigurnost primjene radija-223 za odobrenu indikaciju.
English: In the phase III study, cases of ONJ have been reported in 0.67% patients (4/600) in the Xofigo arm compared to 0.33% patients (1/301) in the placebo arm.
Croatian: U ispitivanju faze III, u 0,67 % bolesnika (4/600) u skupini liječenih lijekom Xofigo prijavljeni su slučajevi osteonekroze čeljusti u usporedbi s 0,33 % bolesnika (1/301) u skupini na placebu.
English: You might be at a higher risk for bone fractures.
Croatian: Moguće je da imate veći rizik za prijelome kostiju.
English: Secondary malignant neoplasms
Croatian: Sekundarne zloćudne novotvorine
English: The clinical efficacy and safety of concurrent initiation of Xofigo, abiraterone acetate and prednisone/prednisolone treatment was assessed in a randomized, placebo-controlled multicenter phase III study (ERA-223 trial) in 806 chemotherapy-naïve patients with asymptomatic or mildly symptomatic castration resistant prostate cancer with bone metastases.
Croatian: Klinička djelotvornost i sigurnost istodobnog početka primjene lijeka Xofigo, abirateronacetata i prednizona/prednizolona ocjenjivana je u randomiziranom, multicentričnom, placebom kontroliranom ispitivanju faze III (ispitivanje ERA-223) u 806 bolesnika s asimptomatskim ili blago simptomatskim rakom prostate rezistentnim na kastraciju s metastazama na kostima, koji prethodno nisu bili liječeni kemoterapijom.
English: No cases of cancer caused by Xofigo have been reported in clinical trials with a follow-up of up to three years.
Croatian: Nije prijavljen nijedan slučaj raka uzrokovan lijekom Xofigo u kliničkim ispitivanjima s praćenjem do tri godine.
English: Updated analysis
Croatian: Ažurirana analiza
English: In a clinical study, the addition of Xofigo to abiraterone acetate and prednisone/prednisolone, increased the incidence of fractures approximately three-fold in the Xofigo arm (see sections 4.8 and 5.1).
Croatian: U kliničkom je ispitivanju dodavanje lijeka Xofigo abirateronacetatu i prednizonu/prednizolonu u skupini koja je primala Xofigo povećalo incidenciju prijeloma otprilike trostruko (vidjeti dijelove 4.8 i 5.1).
English: Limited data are available for patients with moderate (CLCR: 30 to 50 mL/min) renal impairment.
Croatian: Za bolesnike s umjerenim (CLCR: 30 do 50 ml/min) oštećenjem funkcije bubrega dostupni su ograničeni podaci.
English: A statistically significant overall survival benefit of treatment could not be demonstrated in the subgroups of patients with fewer than 6 metastases (HR for radium-223 to placebo 0.901; 95% CI [0.553 -1.466], p=0.674) or a baseline total alkaline phosphatase (ALP) < 220 U/L (HR 0.823; 95% CI [0.633 -1.068], p=0.142) in the phase III ALSYMPCA study.
Croatian: U ispitivanju faze III, ALSYMPCA, nije pokazana statistički značajna korist liječenja za ukupno preživljenje u podskupinama bolesnika s manje od 6 metastaza (HR za radij-223 prema placebu 0,901; 95% CI [0,5531,466]; p=0,674) ili s početnom ukupnom alkalnom fosfatazom (ALP) < 220 U/l (HR 0,823; 95% CI [0,633 - 1,068]; p=0,142).
English: Uterine polyps (endometrial stroma) were observed in female rats after single or repeated administration of ≥ 359 kBq/kg body weight radium-223 dichloride (≥ 6.5 times the clinically recommended activity).
Croatian: Uterini polipi (stroma endometrija) bili su opaženi u ženki štakora nakon jednokratne ili ponovljene primjene radijevog-223 diklorida u dozi ≥ 359 kBq/kg tjelesne težine (≥ 6,5 puta veća od klinički preporučene aktivnosti).
English: A minimal number of abnormal spermatocytes were seen in a few seminiferous tubules in the testes of male rats after a single administration of ≥ 2270 kBq/kg body weight radium-223 dichloride (≥ 41 times the clinically recommended activity).
Croatian: Minimalni broj abnormalnih spermatocita bio je opažen u nekoliko sjemenih kanalića u testisima mužjaka štakora nakon jednokratne primjene radijevog-223 diklorida u dozi ≥ 2270 kBq/kg tjelesne težine (≥ 41 puta veća od klinički preporučene aktivnosti).
English: INSTRUCTION FOR PREPARATION OF RADIOPHARMACEUTICALS This medicinal product should be visually inspected before use.
Croatian: Ovaj je lijek potrebno vizualno pregledati prije primjene.
English: Your doctor might prescribe you a drug to prevent bone fractures before starting or continuing treatment with Xofigo.
Croatian: Vaš će Vam liječnik možda propisati lijek za sprječavanje prijeloma kostiju prije početka ili nastavka liječenja lijekom Xofigo.
English: The most frequent side effects in patients receiving Xofigo (very common [may affect more than 1 in 10 people]) are: - diarrhoea, nausea (feeling sick), vomiting, thrombocytopenia (decrease in the number of blood platelets) and bone fracture.
Croatian: Najčešće nuspojave u bolesnika koji primaju Xofigo (vrlo često [mogu se javiti u više od 1 na 10 osoba]) su: - proljev, mučnina, povraćanje, trombocitopenija (smanjenje broja krvnih pločica) te prijelom kosti.
English: Contact your doctor if you have any questions.
Croatian: Ako imate ikakvih pitanja, obratite se svom liječniku.
English: Storage of Xofigo should be in accordance with national regulation on radioactive materials.
Croatian: Xofigo treba čuvati u skladu s nacionalnim propisima o radioaktivnim materijalima.
English: Storage should be in accordance with national regulation on radioactive materials.
Croatian: Čuvanje treba biti u skladu s nacionalnim propisima o radioaktivnim materijalima.
English: Neutropenia (all grades) was reported in 5% of patients treated with Xofigo and in 1% of patients receiving placebo.
Croatian: Neutropenija (svi stupnjevi) je prijavljena u 5% bolesnika liječenih lijekom Xofigo i u 1% bolesnika koji su primali placebo.
English: - If you experience a bone fracture, your doctor will first stabilise the fractured bone before starting or continuing treatment with Xofigo.
Croatian: - Ako dobijete prijelom kosti, liječnik će prvo stabilizirati prijelom kosti prije početka ili nastavka liječenja lijekom Xofigo.
English: In patients with bone fractures, orthopaedic stabilisation of fractures should be performed before starting or resuming treatment with Xofigo.
Croatian: U bolesnika s prijelomima kosti potrebno je napraviti ortopedsku stabilizaciju prijeloma prije početka ili nastavka liječenja lijekom Xofigo.
English: Overall, the frequency of grade 3 and 4 thrombocytopenia was lower in patients that did not previously receive docetaxel (2.8% in patients treated with Xofigo versus 0.8% in patients receiving placebo) compared to patients that previously received docetaxel (8.9% in patients treated with Xofigo versus 2.9% in patients receiving placebo).
Croatian: Ukupno gledano, učestalost trombocitopenije stupnja 3 i 4 je bila niža u bolesnika koji prethodno nisu primali docetaksel (2,8% u bolesnika liječenih lijekom Xofigo naspram 0,8% u bolesnika koji su primali placebo) u usporedbi s bolesnicima koji su prethodno primali docetaksel (8,9% u bolesnika liječenih lijekom Xofigo naspram 2,9% u bolesnika koji su primali placebo).
English: Blood and lymphatic system disorders
Croatian: Poremećaji krvi i limfnog sustava trombocitopenija neutropenija pancitopenija leukopenija limfopenija
English: Overall, the frequency of grade 3 and 4 neutropenia was lower in patients that did not previously receive docetaxel (0.8% in patients treated with Xofigo versus 0.8% in patients receiving placebo) compared to patients that previously received docetaxel (3.2% in patients treated with Xofigo versus 0.6% in patients receiving placebo).
Croatian: Ukupno gledano, učestalost neutropenije stupnja 3 i 4 je bila niža u bolesnika koji prethodno nisu primali docetaksel (0,8% u bolesnika liječenih lijekom Xofigo naspram 0,8% u bolesnika koji su primali placebo) u usporedbi s bolesnicima koji su prethodno primali docetaksel (3,2% u bolesnika liječenih lijekom Xofigo naspram 0,6% u bolesnika koji su primali placebo).
English: - The active substance is: radium Ra 223 dichloride (radium-223 dichloride).
Croatian: - Djelatna tvar je: radijev Ra 223 diklorid (radijev-223 diklorid).
English: Safety and efficacy of concomitant chemotherapy with Xofigo have not been established.
Croatian: Sigurnost i djelotvornost istodobne primjene kemoterapije s lijekom Xofigo nisu ustanovljene.
English: Dose-limiting myelotoxicity was seen in dogs after single administration of 497 kBq radium-223 dichloride per kg body weight (9 times the clinically recommended activity).
Croatian: Mijelotoksičnost koja ograničava dozu bila je opažena u pasa nakon jednokratne primjene 497 kBq radijevog-223 diklorida po kg tjelesne težine (9 puta veća od klinički preporučene aktivnosti).
English: Therefore, if you suffer from these conditions your doctor will carefully consider if you can be treated with Xofigo.
Croatian: Vaš liječnik će pažljivo razmotriti možete li biti liječeni lijekom Xofigo.
English: Therefore, Xofigo is contraindicated in combination with abiraterone acetate and prednisone/prednisolone (see section 4.3).
Croatian: Stoga je Xofigo kontraindiciran u kombinaciji s abirateronacetatom i prednizonom/prednizolonom (vidjeti dio 4.3).
English: = Body weight (kg)  activity (55 kBq/kg body weight)
Croatian: Volumen koji će se primijeniti (ml) = Tjelesna težina (kg)  aktivnost (55 kBq/kg tjelesne težine) DK faktor  1100 kBq/ml
English: Xofigo 1100 kBq/mL solution for injection radium Ra 223 dichloride
Croatian: Xofigo 1100 kBq/ml otopina za injekciju radijev Ra 223 diklorid
English: This medicine contains the active substance radium Ra 223 dichloride (radium-223 dichloride).
Croatian: Ovaj lijek sadrži djelatnu tvar radijev Ra 223 diklorid (radijev-223 diklorid).
English: The efficacy and safety of cytotoxic chemotherapy performed after treatment with Xofigo has not been established.
Croatian: Djelotvornost i sigurnost primjene citotoksične kemoterapije nakon primjene lijeka Xofigo nisu ustanovljene.
English: Therefore, long-term cumulative radiation exposure may be associated with an increased risk of cancer and hereditary defects.
Croatian: Stoga, dugoročna kumulativna izloženost zračenju može biti povezana s povišenim rizikom za razvoj raka i nasljednih oštećenja.
English: Xofigo contributes to your overall long-term cumulative radiation exposure.
Croatian: Xofigo pridonosi Vašoj ukupnoj dugotrajnoj kumulativnoj izloženosti zračenju.
English: Manufacturer Bayer AS
Croatian: Proizvođač Bayer AS
English: In patients with untreated imminent or established spinal cord compression, treatment with standard of care, as clinically indicated, should be completed before starting or resuming treatment with Xofigo.
Croatian: U bolesnika s neliječenom prijetećom ili ustanovljenom kompresijom kralježnične moždine potrebno je završiti liječenje standardnom skrbi, prema kliničkoj indikaciji, prije početka ili nastavka liječenja lijekom Xofigo.
English: Diarrhoea Vomiting Nausea
Croatian: Poremećaji probavnog sustava proljev povraćanje mučnina
English: Xofigo should only be administered after a careful benefit-risk assessment in patients with acute inflammatory bowel disease.
Croatian: Xofigo se smije primjenjivati u bolesnika s akutnom upalnom bolesti crijeva samo nakon pažljive procjene omjera koristi i rizika.
English: As interactions with calcium and phosphate cannot be excluded, pausing supplementation with these substances and/or Vitamin D should be considered some days before starting with Xofigo treatment.
Croatian: S obzirom da se interakcije s kalcijem i fosfatima ne mogu isključiti, mora se razmotriti prestanak uzimanja nadomjestaka ovih tvari i/ili vitamina
English: Thrombocytopenia (all grades) occurred in 11.5% of patients treated with Xofigo and 5.6% of patients receiving placebo.
Croatian: Trombocitopenija (svi stupnjevi) je nastala u 11,5% bolesnika liječenih lijekom Xofigo i 5,6% bolesnika koji su primali placebo.
English: Xofigo is not to be used in women who are, or may be, pregnant or breast-feeding.
Croatian: Xofigo se ne smije primjenjivati u trudnica, žena koje bi mogle biti trudne ili doje.
English: Compared with placebo, there was a significant difference in favour of Xofigo for all five serum biomarkers for bone turnover studied in a phase II randomised study (bone formation markers: bone alkaline phosphatase [ALP], total ALP and procollagen I N propeptide [PINP], bone resorption markers: C-terminal crosslinking telopeptide of type I collagen / serum C-terminal crosslinked telopeptide of type I collagen [S-CTX-I] and type I collagen crosslinked C-telopeptide [ICTP]).
Croatian: U usporedbi s placebom, postojala je značajna razlika u korist lijeka Xofigo za svih pet serumskih bioloških biljega pregradnje kosti ispitivanih u randomiziranom ispitivanju faze II (biljezi stvaranja kosti: koštana alkalna fosfataza [ALP], ukupna ALP i prokolagen I N propeptid [PINP], biljezi resorpcije kosti:
English: The most appropriate MedDRA term is used to describe a certain reaction and its synonyms and related conditions.
Croatian: Za opis određene reakcije i njezinih sinonima te s njom povezanih stanja odabran je najprikladniji MedDRA-izraz.
English: Long-term cumulative radiation exposure may increase your risk for developing cancer (in particular of bone cancer and leukaemia) and hereditary abnormalities.
Croatian: Dugotrajna kumulativna izloženost zračenju može povisiti Vaš rizik za razvoj raka (posebno raka kostiju i leukemije) i nasljednih poremećaja.
English: Xofigo is contraindicated in combination with abiraterone acetate and prednisone/prednisolone (see section 4.4).
Croatian: Xofigo je kontraindiciran u kombinaciji s abirateronacetatom i prednizonom/prednizolonom (vidjeti dio 4.4).
English: The use of Xofigo is therefore not recommended for treatment of adults with castration-resistant prostate cancer and only asymptomatic bone metastases.
Croatian: Stoga se primjena lijeka Xofigo za liječenje odraslih s rakom prostate rezistentnim na kastraciju i samo asimptomatskim koštanim metastazama ne preporučuje.
English: Each vial contains 6 mL of solution (6.6 MBq radium-223 dichloride at the reference date).
Croatian: Jedna bočica sadrži 6 ml otopine (6,6 MBq radijevog-223 diklorida na referentni datum).
English: Grade 3 and 4 thrombocytopenia was observed in 6.3% of patients treated with Xofigo and in 2% of patients receiving placebo (see section 4.4).
Croatian: Trombocitopenija stupnja 3 i 4 bila je opažena u 6,3% bolesnika liječenih lijekom Xofigo i u 2% bolesnika koji su primali placebo (vidjeti dio 4.4).
English: Grade 3 and 4 neutropenia was observed in 2.2% of patients treated with Xofigo and in 0.7% of patients receiving placebo.
Croatian: Neutropenija stupnja 3 i 4 bila je opažena u 2,2% bolesnika liječenih lijekom Xofigo i 0,7% bolesnika koji su primali placebo.
English: Xofigo 1100 kBq/mL solution for injection radium Ra 223 dichloride For intravenous use.
Croatian: Xofigo 1100 kBq/ml otopina za injekciju radijev Ra 223 diklorid Za intravensku primjenu.
English: Safety and efficacy of Xofigo have not been studied in patients with hepatic impairment.
Croatian: Sigurnost i djelotvornost lijeka Xofigo nisu ispitane u bolesnika s oštećenjem funkcije jetre.
English: Each vial contains 6 mL of solution (6600 kBq radium-223 dichloride at the reference date).
Croatian: Jedna bočica sadrži 6 ml otopine (6600 kBq radijevog-223 diklorida na referentni datum).
English: Alpha1 emission (Gy/MBq)
Croatian: Alfa1 zračenje (Gy/MBq)
English: The vial is stored in a lead pot.
Croatian: Bočica se čuva u olovnoj posudi.
English: Musculoskeletal and connective tissue disorders
Croatian: Poremećaji mišićnokoštanog sustava i vezivnog tkiva prijelom kosti osteoporoza
English: Xofigo contributes to a patient's overall long-term cumulative radiation exposure.
Croatian: Xofigo pridonosi ukupnoj dugotrajnoj kumulativnoj izloženosti bolesnika zračenju.
English: Long-term cumulative radiation exposure may be associated with an increased risk of cancer and hereditary defects.
Croatian: Dugotrajna kumulativna izloženost zračenju može biti povezana s povećanim rizikom za razvoj raka i nasljednih oštećenja.
English: Each mL of solution contains 1100 kBq radium-223 dichloride, corresponding to 0.58 ng radium-223 at the reference date.
Croatian: Jedan ml otopine sadrži 1100 kBq radijevog-223 diklorida, što odgovara 0,58 ng radija-223 na referentni datum.
English: 2LLI: lower large intestine
Croatian: 2 DDC: donji dio debelog crijeva